* This chart and data were pulled from the AI in Drug Discovery and Development report by Insider Intelligence. Purchase the report here to get immediate access to the full analysis. |
The pharmaceutical industry has been lagging behind other industries when it comes to digitization, but incumbents are now signaling their interest in digital health. Pharma companies became much more active investors in digital health this year: They were responsible for 20% of digital health funding rounds in the first half of 2020—up from 11% across 2019.
AI is the most disruptive technology in pharma—incumbents are tapping the tech to slash the time and resources needed to bring a drug to market. But the painstaking process of bringing a drug to market isn't only creating opportunities for AI-focused startups—tech giants are also lending their AI, cloud, and data prowess to land pharma deals. |
- Sanofi works with Google to deploy AI in a range of areas, with the broad goal of speeding up development. The duo launched a partnership last year to deploy deep analytics across data sets to better understand diseases and extract patient insights—which should open up the opportunity for Sanofi to research and develop more personalized approaches to treatments.
|
- Novartis tapped Microsoft to apply AI to a wide array of procedures, including speeding up drug discovery, per Financial Times. Through the five-year agreement—finalized in 2019—Microsoft develops AI to be applied across all of Novartis' business, from finance to manufacturing. Microsoft is also applying deep learning algorithms to accelerate and improve the accuracy of drug development.
|
- Moderna leans on AWS' computational capabilities, powerful analytics, and ability to automate manufacturing processes to speed up the development process. Moderna has slid into the spotlight...
|
|
|
Other report highlights you don’t want to miss… |
| |
| This is just a preview of the information and insights you'll find in the AI in Drug Discovery and Development report by Insider Intelligence. Purchase the report today for $495 to access the full analysis. |
